[CAS NO. 1579965-12-0] GSK2983559freeacid
PRODUCTS SPECIFICATIONS [1579965-12-0]
DESCRIPTION [1579965-12-0]
Overview
| MDL | MFCD30489430 |
|---|---|
| Molecular Weight | 538.53 |
| Molecular Formula | C21H23N4O7PS2 |
| SMILES | CC(C)(C)S(C(C(OCCOP(O)(O)=O)=CC1=NC=N2)=CC1=C2NC3=CC(N=CS4)=C4C=C3)(=O)=O |
Summary
GSK2983559 free acid (compound 3) is an orally active and potent receptor interacting protein 2 ( RIP2 ) kinase inhibitor. GSK2983559 free acid can block many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples [1] .
IC50 & Target
|
RIPK2 |
In Vitro
GSK2983559 (1-1024 nM; 2 h) blocks MDP-induced IL-8 in THP-1 cells [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [2]
| Cell Line: | THP-1 cells |
| Concentration: | 1-1024 nM |
| Incubation Time: | 2 hours |
| Result: | Inhibited IL-8 production with an IC 50 of 1.34 nM. |
In Vivo
GSK2983559 (oral gavage; 3 and 10 mg/kg; once) inhibits effectively MDP-induced IL-6 in mouse [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | C57BL/6 mice (female) injected with MDP (100 μg) [2] |
| Dosage: | 3 and 10 mg/kg |
| Administration: | Oral gavage; 3 and 10 mg/kg; once |
| Result: | Suppressed serum IL-6 levels in a dose-dependent manner. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03358407 | GlaxoSmithKline |
Inflammatory Bowel Diseases
|
January 11, 2018 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 5 mg/mL ( 9.28 mM ; ultrasonic and warming and heat to 80°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.8569 mL | 9.2845 mL | 18.5691 mL |
| 5 mM | 0.3714 mL | 1.8569 mL | 3.7138 mL |
| 10 mM | --- | --- | --- |
References
- [1] Haile PA, et al. Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammat
- [2] Shuwei Wu, et al. Design, synthesis, and structure-activity relationship of novel RIPK2 inhibitors. Bioorg Med Chem Lett. 2022 Sep 2;75:128968.